Serotonin and GI clinical disorders

Neuropharmacology

Volumn 55, Issue 6, 2008, Pages 1072-1080

  Spiller, Robin ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Constipation; Diarrhoea; Inflammation; Intestine; Serotonin; Transporter

Indexed keywords

ALOSETRON; CILANSETRON; ENZYME INHIBITOR; ONDANSETRON; PRUCALOPRIDE; RAMOSETRON; SEROTONIN; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELIAC DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DYSPEPSIA; ENTEROCHROMAFFIN CELL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HUMAN; INFLAMMATION; INTERNEURON; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE SECRETION; IRRITABLE COLON; MYENTERIC PLEXUS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SEROTONIN RELEASE; T LYMPHOCYTE; VOMITING;

ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; MODELS, BIOLOGICAL; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 53449094757     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.07.016     Document Type: Article

References (119)

1. Atkinson W., Lockhart S., Whorwell P.J., Keevil B., and Houghton L.A. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130 (2006) 34-43
2. Bardhan K.D., Bodemar G., Geldof H., Schutz E., Heath A., Mills J.G., and Jacques L.A. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 14 (2000) 23-34
3. Bearcroft C.P., Perrett D., and Farthing M.J. 5-hydroxytryptamine release into human jejunum by cholera toxin. Gut 39 (1996) 528-531
4. Bearcroft C.P., Perrett D., and Farthing M.J. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 42 (1998) 42-46
5. Bercik P., Wang L., Verdu E.F., Mao Y.K., Blennerhassett P., Khan W.I., Kean I., Tougas G., and Collins S.M. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 127 (2004) 179-187
6. Berman S.M., Chang L., Suyenobu B., Derbyshire S.W., Stains J., Fitzgerald L., Mandelkern M., Hamm L., Vogt B., Naliboff B.D., and Mayer E.A. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 123 (2002) 969-977
7. Bishop A.E., Pietroletti R., Taat C.W., Brummelkamp W.H., and Polak J.M. Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch. A Pathol. Anat. Histopathol. 410 (1987) 391-396
8. Bjornsson E.S., Chey W.D., Ladabaum U., Woods M.L., Hooper F.G., Owyang C., and Hasler W.L. Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex. Am. J. Physiol. 275 (1998) G498-G505
9. Borman R.A., and Burleigh D.E. Heterogeneity of 5-HT receptors mediating secretion in the human intestine. Ann. N. Y. Acad. Sci. 812 (1997) 224-225
10. Bouras E.P., Camilleri M., Burton D.D., and McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 44 (1999) 682-686
11. Braun T., Voland P., Kunz L., Prinz C., and Gratzl M. Enterochromaffin cells of the human gut: sensors for spices and odorants. Gastroenterology 132 (2007) 1890-1901
12. de Bruine A.P., Dinjens W.N., Zijlema J.H., Lenders M.H., and Bosman F.T. Renewal of enterochromaffin cells in the rat caecum. Anat. Rec. 233 (1992) 75-82
13. Camilleri M., Andrews C.N., Bharucha A.E., Carlson P.J., Ferber I., Stephens D., Smyrk T.C., Urrutia R., Aerssens J., Thielemans L., Gohlmann H., van dW I., and Coulie B. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 132 (2007) 17-25
14. Camilleri M., Atanasova E., Carlson P.J., Ahmad U., Kim H.J., Viramontes B.E., McKinzie S., and Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123 (2002) 425-432
15. Camilleri M., Kerstens R., Rykx A., and Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358 (2008) 2344-2354
16. Camilleri M., Mayer E.A., Drossman D.A., Heath A., Dukes G.E., McSorley D., Kong S., Mangel A.W., and Northcutt A.R. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol. Ther. 13 (1999) 1149-1159
17. Camilleri M., Northcutt A.R., Kong S., Dukes G.E., McSorley D., and Mangel A.W. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355 (2000) 1035-1040
18. Cann P.A., Read N.W., Brown C., Hobson N., and Holdsworth C.D. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 24 (1983) 405-411
19. Carling R.S., Degg T.J., Allen K.R., Bax N.D., and Barth J.H. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann. Clin. Biochem. 39 (2002) 577-582
20. Cellek S., John A.K., Thangiah R., Dass N.B., Bassil A.K., Jarvie E.M., Lalude O., Vivekanandan S., and Sanger G.J. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol. Motil. 18 (2006) 853-861
21. Challacombe D.N., Dawkins P.D., and Baker P. Increased tissue concentrations of 5-hydroxytryptamine in the duodenal mucosa of patients with coeliac disease. Gut 18 (1977) 882-886
22. Chang L., Chey W.D., Harris L., Olden K., Surawicz C., and Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am. J. Gastroenterol. 101 (2006) 1069-1079
23. Chejfec G., Falkmer S., Askensten U., Grimelius L., and Gould V.E. Neuroendocrine tumors of the gastrointestinal tract. Pathol. Res. Pract. 183 (1988) 143-154
24. Chiaravalloti G., Marazziti D., Batistini A., Favilli T., Ughi C., Ceccarelli M., and Cassano G.B. Platelet serotonin transporter in coeliac disease. Acta Paediatr. 86 (1997) 696-699
25. Christofi F.L., Kim M., Wunderlich J.E., Xue J., Suntres Z., Cardounel A., Javed N.H., Yu J.G., Grants I., and Cooke H.J. Endogenous adenosine differentially modulates 5-hydroxytryptamine release from a human enterochromaffin cell model. Gastroenterology 127 (2004) 188-202
26. Coates M.D., Brooks E.M., Costedio M.M., Ganguly E.K., Strader D.B., Callahan M.J., Mawe G.M., and Moses P.L. Opiate induced constipation is not associated with changes in serotonin signaling in the rectal mucosa as observed in ibs and colitis. Gastroenterology 134 (2008) A-682
27. Coates M.D., Mahoney C.R., Linden D.R., Sampson J.E., Chen J., Blaszyk H., Crowell M.D., Sharkey K.A., Gershon M.D., Mawe G.M., and Moses P.L. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126 (2004) 1657-1664
28. Coleman N.S., Foley S., Dunlop S.P., Wheatcroft J., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., Holmes G.K., and Spiller R.C. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin. Gastroenterol. Hepatol. 4 (2006) 874-881
29. Coleman N.S., Marciani L., Blackshaw E., Wright J., Parker M., Yano T., Yamazaki S., Chan P.Q., Wilde K., Gowland P.A., Perkins A.C., and Spiller R.C. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment. Pharmacol. Ther. 18 (2003) 1039-1048
30. Coremans G., Kerstens R., De P.M., and Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 67 (2003) 82-89
31. Cubeddu L.X., Hoffmann I.S., Fuenmayor N.T., and Malave J.J. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br. J. Cancer 66 (1992) 198-203
32. De Maeyer J.H., Lefebvre R.A., and Schuurkes J.A. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 20 (2008) 99-112
33. De Schryver A.M., Andriesse G.I., Samsom M., Smout A.J., Gooszen H.G., and Akkermans L.M. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment. Pharmacol. Ther. 16 (2002) 603-612
34. Degen L., Matzinger D., Merz M., Appel-Dingemanse S., Osborne S., Luchinger S., Bertold R., Maecke H., and Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther. 15 (2001) 1745-1751
35. Delvaux M., Louvel D., Mamet J.P., Campos-Oriola R., and Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 12 (1998) 849-855
36. Donowitz M., Charney A.N., and Heffernan J.M. Effect of serotonin treatment on intestinal transport in the rabbit. Am. J. Physiol. 232 (1977) E85-E94
37. DuBois A., Vach W., Siebert C., Holy R., Ledergerber M., Wechsel U., and Kriesinger-Schroeder H. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens. Support. Care Cancer 5 (1997) 212-218
38. Dunlop S.P., Coleman N.S., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., and Spiller R.C. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 3 (2005) 349-357
39. Dunlop S.P., Jenkins D., Neal K.R., and Spiller R.C. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125 (2003) 1651-1659
40. Eherer A.J., Hinterleitner T.A., Petritsch W., Holzer-Petsche U., Beubler E., and Krejs G.J. Effect of 5-hydroxytryptamine antagonists on cholera toxin-induced secretion in the human jejunum. Eur. J. Clin. Invest. 24 (1994) 664-668
41. El Salhy M., Danielsson A., Stenling R., and Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J. Intern. Med. 242 (1997) 413-419
42. Evans B.W., Clark W.K., Moore D.J., and Whorwell P.J. Tegaserod for the treatment of irritable bowel syndrome. Cochrane (2004) Database. Syst. Rev., CD003960
43. Ferrara A., Zinner M.J., and Jaffe B.M. Intraluminal release of serotonin, substance P, and gastrin in the canine small intestine. Dig. Dis. Sci. 32 (1987) 289-294
44. 2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007) G779-G784
45. Foley S., Coleman N., Holmes G.K.T., Bennett A., and Spiller R.C. Serotonin transporter expression is reduced in celiac disease. Gastroenterology 130 (2006) A740
46. Forsberg E.J., and Miller R.J. Regulation of serotonin release from rabbit intestinal enterochromaffin cells. J. Pharmacol. Exp. Ther. 227 (1983) 755-766
47. Foxx-Orenstein A., Camilleri M., Gershon M.D., Linden D.R., Mawe G., Lewis J.T., Jensen K.L., Talley N., Szurszewski J.H., and Zinsmeister A. Alterations in intestinal serotonin expression in dyspepsia and irritable bowel syndrome. Gastroenterology 132 (2007) A72
48. Fujimiya M., Okumiya K., and Kuwahara A. Immunoelectron microscopic study of the luminal release of serotonin from rat enterochromaffin cells induced by high intraluminal pressure. Histochem. Cell Biol. 108 (1997) 105-113
49. Fujita T., Yokota S., Sawada M., Majima M., Ohtani Y., and Kumagai Y. Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J. Clin. Pharm. Ther. 30 (2005) 611-622
50. Fukumoto S., Tatewaki M., Yamada T., Fujimiya M., Mantyh C., Voss M., Eubanks S., Harris M., Pappas T.N., and Takahashi T. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 (2003) R1269-R1276
51. Gershon M.D. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharmacol. Ther. 13 Suppl. 2 (1999) 15-30
52. Gill R.K., Pant N., Saksena S., Singla A., Nazir T.M., Vohwinkel L., Turner J.R., Goldstein J., Alrefai W.A., and Dudeja P.K. Function, expression, and characterization of the serotonin transporter in the native human intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 294 (2008) G254-G262
53. Greenberg B.D., Tolliver T.J., Huang S.J., Li Q., Bengel D., and Murphy D.L. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 88 (1999) 83-87
54. Grider J.R., Foxx-Orenstein A.E., and Jin J.G. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 115 (1998) 370-380
55. Grondahl M.L., Jensen G.M., Nielsen C.G., Skadhauge E., Olsen J.E., and Hansen M.B. Secretory pathways in Salmonella typhimurium-induced fluid accumulation in the porcine small intestine. J. Med. Microbiol. 47 (1998) 151-157
56. Hansen M.B., and Jaffe B.M. 5-HT receptor subtypes involved in luminal serotonin-induced secretion in rat intestine in vivo. J. Surg. Res. 56 (1994) 277-287
57. Hawthorn J., Ostler K.J., and Andrews P.L. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q. J. Exp. Physiol. 73 (1988) 7-21
58. Hesketh P.J., Grunberg S.M., Gralla R.J., Warr D.G., Roila F., de Wit R., Chawla S.P., Carides A.D., Ianus J., Elmer M.E., Evans J.K., Beck K., Reines S., and Horgan K.J. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J. Clin. Oncol. 21 (2003) 4112-4119
59. Hirata T., Funatsu T., Keto Y., Nakata M., and Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology 15 (2007) 5-9
60. Houghton L.A., Foster J.M., and Whorwell P.J. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol. Ther. 14 (2000) 775-782
61. Hutchinson R., Notghi A., Smith N.B., Harding L.K., and Kumar D. Scintigraphic measurement of ileocaecal transit in irritable bowel syndrome and chronic idiopathic constipation. Gut 36 (1995) 585-589
62. Jones R.H., Holtmann G., Rodrigo L., Ehsanullah R.S., Crompton P.M., Jacques L.A., and Mills J.G. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment. Pharmacol. Ther. 13 (1999) 1419-1427
63. Kellum J.M., Albuquerque F.C., Stoner M.C., and Harris R.P. Stroking human jejunal mucosa induces 5-HT release and Cl- secretion via afferent neurons and 5-HT4 receptors. Am. J. Physiol. 277 (1999) G515-G520
64. Kerckhoffs A.P., Ter Linde J.J., Akkermans L.M., and Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol. Motil. (2008)
65. Kidd M., Eick G.N., Modlin I.M., Pfragner R., Champaneria M.C., and Murren J. Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J. Mol. Endocrinol. 38 (2007) 181-192
66. Kim M., Christofi F.L., Xue J., Robinson J.M., and Cooke H.J. Mechanically evoked 5-hydroxytryptamine release is mediated by caveolin-associated cholesterol rich membrane domains. Neurogastroenterol. Motil. 19 (2007) 309-317
67. Kim M., Javed N.H., Yu J.G., Christofi F., and Cooke H.J. Mechanical stimulation activates Galphaq signaling pathways and 5-hydroxytryptamine release from human carcinoid BON cells. J. Clin. Invest. 108 (2001) 1051-1059
68. Kordasti S., Sjovall H., Lundgren O., and Svensson L. Serotonin and vasoactive intestinal peptide antagonists attenuate rotavirus diarrhoea. Gut 53 (2004) 952-957
69. Kuemmerle J.F., Kraus H., and Kellum J.M. Serotonin release is mediated by muscarinic receptors on duodenal mucosal cells. J. Surg. Res. 43 (1987) 139-142
70. Kuemmerle J.F., Smith E.H., Borum E.H., and Kellum J.M. Beta-adrenoceptors on duodenal mucosal cells mediate venous serotonin release. J. Surg. Res. 44 (1988) 740-744
71. Kyosola K., Penttila O., and Salaspuro M. Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand. J. Gastroenterol. 12 (1977) 363-367
72. Leclere P.G., Prins N.H., Schuurkes J.A., and Lefebvre R.A. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol. Motil. 17 (2005) 366-375
73. Linden D.R., Chen J.X., Gershon M.D., Sharkey K.A., and Mawe G.M. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 285 (2003) G207-G216
74. Linden D.R., Foley K.F., McQuoid C., Simpson J., Sharkey K.A., and Mawe G.M. Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol. Motil. 17 (2005) 565-574
75. Liu Q., Yang Q., Sun W., Vogel P., Heydorn W., Yu X.Q., Hu Z., Yu W., Jonas B., Pineda R., Calderon-Gay V., Germann M., O'Neill E., Brommage R., Cullinan E., Platt K., Wilson A., Powell D., Sands A., Zambrowicz B., and Shi Z.C. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J. Pharmacol. Exp. Ther. 325 (2008) 47-55
76. Lordal M., Wallen H., Hjemdahl P., Beck O., and Hellstrom P.M. Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans. Clin. Sci. (Colch.) 94 (1998) 663-670
77. Lu C.L., Chen C.Y., Chang F.Y., and Lee S.D. Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: an Oriental study. Clin. Sci. (Lond) 95 (1998) 165-169
78. Magro F., Vieira-Coelho M.A., Fraga S., Serrao M.P., Veloso F.T., Ribeiro T., and Soares-da-Silva P. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig. Dis. Sci. 47 (2002) 216-224
79. Mahesh R., Perumal R.V., and Pandi P.V. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie 60 (2005) 83-96
80. Maxton D.G., Morris J., and Whorwell P.J. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?. Aliment. Pharmacol. Ther. 10 (1996) 595-599
81. McLean P.G., and Coupar I.M. Investigation into the effect of 5-hydroxytryptamine on fluid transport in the rat small intestine. Gen. Pharmacol. 30 (1998) 227-231
82. Minderhoud I.M., Oldenburg B., Schipper M.E., Ter Linde J.J., and Samsom M. Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin. Gastroenterol. Hepatol. 5 (2007) 714-720
83. Miwa J., Echizen H., Matsueda K., and Umeda N. Patients with constipation-predominant irritable bowel syndrome (ibs) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 63 (2001) 188-194
84. Moore B.A., Sharkey K.A., and Mantle M. Role of 5-HT in cholera toxin-induced mucin secretion in the rat small intestine. Am. J. Physiol. 270 (1996) G1001-G1009
85. Motomura Y., Ghia J.E., Wang H., Akiho H., El-Sharkawy R.T., Collins M., Wan Y., McLaughlin J.T., and Khan W.I. Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut 57 (2008) 475-481
86. Moyana T.N., and Shukoor S. Gastrointestinal endocrine cell hyperplasia in celiac disease: a selective proliferative process of serotonergic cells. Mod. Pathol. 4 (1991) 419-423
87. Muller-Lissner S.A., Fumagalli I., Bardhan K.D., Pace F., Pecher E., Nault B., and Ruegg P. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. 15 (2001) 1655-1666
88. Neya T., Mizutani M., and Yamasato T. Role of 5-HT3 receptors in peristaltic reflex elicited by stroking the mucosa in the canine jejunum. J. Physiol. 471 (1993) 159-173
89. Novick J., Miner P., Krause R., Glebas K., Bliesath H., Ligozio G., Ruegg P., and Lefkowitz M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 16 (2002) 1877-1888
90. O'Hara J.R., Skinn A.C., MacNaughton W.K., Sherman P.M., and Sharkey K.A. Consequences of Citrobacter rodentium infection on enteroendocrine cells and the enteric nervous system in the mouse colon. Cell Microbiol. 8 (2006) 646-660
91. Oshima S., Fujimura M., and Fukimiya M. Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate. Histochem. Cell Biol. 112 (1999) 257-263
92. von der Ohe M.R., Camilleri M., and Kvols L.K. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 106 (1994) 1184-1189
93. von der Ohe M.R., Camilleri M., Kvols L.K., and Thomforde G.M. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N. Engl. J. Med. 329 (1993) 1073-1078
94. von der Ohe M.R., Hanson R.B., and Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 35 (1994) 536-541
95. Pietroletti R., Blaauwgeers J.L., Taat C.W., Simi M., Brummelkamp W.H., and Becker A.E. Intestinal endocrine cells in radiation enteritis. Surg. Gynecol. Obstet. 169 (1989) 127-130
96. Prather C.M., Camilleri M., Zinsmeister A.R., McKinzie S., and Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118 (2000) 463-468
97. Prior A., and Read N.W. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 7 (1993) 175-180
98. Qian Y., Galli A., Ramamoorthy S., Risso S., DeFelice L.J., and Blakely R.D. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J. Neurosci. 17 (1997) 45-57
99. Racke K., Schworer H., Agoston D.V., and Kilbinger H. Evidence that neuronally released vasoactive intestinal polypeptide inhibits the release of serotonin from enterochromaffin cells of the guinea pig small intestine. Acta Endocrinol. (Copenh) 124 (1991) 203-207
100. Ramamoorthy S., and Blakely R.D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285 (1999) 763-766
101. Rubin G., de Wit N., Meineche-Schmidt V., Seifert B., Hall N.P., and Hungin A.P. Identification and diagnosis of patients with irritable bowel syndrome in primary care: nominal group technique. Gut 54 (2005) A3
102. Ruszniewski P., Ish-Shalom S., Wymenga M., O'Toole D., Arnold R., Tomassetti P., Bax N., Caplin M., Eriksson B., Glaser B., Ducreux M., Lombard-Bohas C., de Herder W.W., Delle F.G., Reed N., Seitz J.F., Van C.E., Grossman A., Rougier P., Schmidt W., and Wiedenmann B. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80 (2004) 244-251
103. Sanders D.S., Carter M.J., Hurlstone D.P., Pearce A., Ward A.M., McAlindon M.E., and Lobo A.J. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 358 (2001) 1504-1508
104. Saslow S.B., Scolapio J.S., Camilleri M., Forstrom L.A., Thomforde G.M., Burton D.D., Rubin J., Pitot H.C., and Zinsmeister A.R. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut 42 (1998) 628-634
105. Schworer H., Racke K., and Kilbinger H. GABA receptors are involved in the modulation of the release of 5-hydroxytryptamine from the vascularly perfused small intestine of the guinea-pig. Eur. J. Pharmacol. 165 (1989) 29-37
106. Siriwardena A., and Kellum Jr. J.M. A 5-HT2 receptor mediates serotonin-induced electrolyte transport in rat left colon. J. Surg. Res. 55 (1993) 323-329
107. Sjolund K., and Nobin A. Increased levels of plasma 5-hydroxytryptamine in patients with coeliac disease. Scand. J. Gastroenterol. 20 (1985) 304-308
108. Sjolund K., Sanden G., Hakanson R., and Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 85 (1983) 1120-1130
109. Spiller R.C. Postinfectious irritable bowel syndrome. Gastroenterology 124 (2003) 1662-1671
110. Sun E.A., Snape W.J.J., Cohen S., and Renny A. The role of opiate receptors and cholinergic neurons in the gastrocolonic response. Gastroenterology 82 (1982) 689-693
111. Talley N.J., Phillips S.F., Haddad A., Miller L.J., Twomey C., Zinsmeister A.R., MacCarty R.L., and Ciociola A. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig. Dis. Sci. 35 (1990) 477-480
112. Turvill J.L., Connor P., and Farthing M.J. The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br. J. Pharmacol. 130 (2000) 1031-1036
113. Wang H., Steeds J., Motomura Y., Deng Y., Verma-Gandhu M., El Sharkawy R.T., McLaughlin J.T., Grencis R.K., and Khan W.I. CD4 + T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut (2007)
114. Westerholm-Ormio M., Garioch J., Ketola I., and Savilahti E. Inflammatory cytokines in small intestinal mucosa of patients with potential coeliac disease. Clin. Exp. Immunol. 128 (2002) 94-101
115. Wheatcroft J., Wakelin D., Smith A., Mahoney C.R., Mawe G., and Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol. Motil. 17 (2005) 863-870
116. Wheeler E.E., and Challacombe D.N. Quantification of enterochromaffin cells with serotonin immunoreactivity in the duodenal mucosa in coeliac disease. Arch. Dis. Child. 59 (1984) 523-527
117. Wiley J., Tatum D., Keinath R., and Chung O.Y. Participation of gastric mechanoreceptors and intestinal chemoreceptors in the gastrocolonic response. Gastroenterology 94 (1988) 1144-1149
118. Yeo C.J., Couse N.F., and Zinner M.J. Serotonin and substance P stimulate intestinal secretion in the isolated perfused ileum. Surgery 105 (1989) 86-92
119. Zighelboim J., Talley N.J., Phillips S.F., Harmsen W.S., and Zinsmeister A.R. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig. Dis. Sci. 40 (1995) 819-827